表紙
市場調查報告書

遺傳基因面板的全球市場:2020年∼2024年

Gene Panel Market by Product and Geography - Forecast and Analysis 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 919943
出版日期 內容資訊 英文 149 Pages
訂單完成後即時交付
價格
Back to Top
遺傳基因面板的全球市場:2020年∼2024年 Gene Panel Market by Product and Geography - Forecast and Analysis 2020-2024
出版日期: 2019年12月11日內容資訊: 英文 149 Pages
簡介

全球遺傳基因面板市場上,癌症標靶治療的遺傳基因面板的使用增加,有遺傳性疾病的人增加,NGS遺傳基因面板檢驗的成本的削減等成為成長促進因素,在預測期間內預計以約18%的年複合成長率擴大。但,大規模的NGS遺傳基因面板的實行的課題,幾個遺傳基因變異缺乏有效治療方法,及遺傳基因面板試驗的複雜化,可能妨礙在預測期間內遺傳基因面板產業的成長。

本報告提供全球遺傳基因面板市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 價值鏈分析
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2019年)
  • 市場規模及預測(2019年∼2024年)
  • 市場預測

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各產品

  • 市場區隔:各產品
  • 各產品比較:市場規模及預測(2019年∼2024年)
  • 小規模面板檢驗
  • 大規模面板檢驗
  • 市場機會:各產品

第7章 客戶形勢

第8章 地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2019年∼2024年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 合作的增加
  • 消費者直銷型檢驗的利用增加
  • 為了確認患者的潛在副作用有效利用遺傳基因面板

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭方案

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Agilent Technologies Inc.
  • ArcherDx Inc.
  • BGI Genomics Co. Ltd.
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd.
  • GENEWIZ Inc.
  • Novogene Corp.
  • Personalis Inc.
  • QIAGEN NV
  • Thermo Fisher Scientific Inc.

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR40613

About this market

Technavio's gene panel market analysis considers sales from small panel testing and large panel testing products. Our study also finds the sales of gene panels in Asia, Europe, North America, and ROW. In 2019, the small panel testing segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the rising need to identify a known gene mutation will play a significant role in the small panel testing segment to maintain its market position. Also, our global gene panel market report looks at factors such as the growing use of gene panels in cancer-targeted therapies, increasing the number of people with genetic disorders, and decreasing the cost of NGS gene panel tests. However, challenges in implementing large NGS gene panels, lack of effective treatment for several genetic mutations, and the growing complexity of gene panel tests may hamper the growth of the gene panel industry over the forecast period.

Overview

Growing use of gene panels in cancer-targeted therapies

Pharmaceutical companies are investing heavily in research activities to develop targeted therapies for the treatment of cancer. This is driving the demand for gene panels as they are used in the development of targeted therapies for cancer. Gene panel testing provides a wide range of benefits such as providing the genetic basis of an individual's response to therapy. NGS-based gene panel tests are becoming popular as the first choice for cancer care as they are cost-effective, provide genomic data in a brief time, and examine only clinically important genes. This is driving the use of gene panels to evaluate effective treatments for cancer, which will lead to the expansion of the global gene panel market at a CAGR of about 18% during the forecast period.

Rising use of direct-to-consumer tests

The global gene panel market is expected to benefit from the increase in the use of direct-to-consumer tests. In this method, commercial laboratories provide genetic testing directly to consumers without the involvement of a healthcare professional or an authorization for payment by a third-party payer. The easy access and the increasingly affordable options associated with direct-to-consumer genomic testing have helped the technique gain significant popularity over the recent years. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global gene panel market during the forecast period 2020-2024, view our report.

Competitive Landscape

With the presence of a few major players, the global gene panel market is concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading gene panel manufacturers, that include Agilent Technologies Inc., ArcherDx Inc., BGI Genomics Co. Ltd., Eurofins Scientific SE, F. Hoffmann-La Roche Ltd., GENEWIZ Inc., Novogene Corp., Personalis Inc., QIAGEN NV, and Thermo Fisher Scientific Inc.

Also, the gene panel market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Value Chain Analysis
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024
  • Market Outlook

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Small panel testing - Market size and forecast 2019-2024
  • Large panel testing - Market size and forecast 2019-2024
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Increasing number of collaborations
  • Rising use of direct-to-consumer tests
  • Use of gene panels to identify potential side effects in patients

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Agilent Technologies Inc.
  • ArcherDx Inc.
  • BGI Genomics Co. Ltd.
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd.
  • GENEWIZ Inc.
  • Novogene Corp.
  • Personalis Inc.
  • QIAGEN NV
  • Thermo Fisher Scientific Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Global life sciences tools and services market
  • Exhibit 02: Segments of global life sciences tools and services market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Vendors: Key product offerings
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2019
  • Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
  • Exhibit 10: Five forces analysis 2019
  • Exhibit 11: Five forces analysis 2024
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2019
  • Exhibit 18: Product - Market share 2019-2024 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Small panel testing - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 21: Small panel testing - Year-over-year growth 2020-2024 (%)
  • Exhibit 22: Large panel testing - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 23: Large panel testing - Year-over-year growth 2020-2024 (%)
  • Exhibit 24: Market opportunity by product
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2019-2024 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2020-2024 (%)
  • Exhibit 30: Europe - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 31: Europe - Year-over-year growth 2020-2024 (%)
  • Exhibit 32: Asia - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 33: Asia - Year-over-year growth 2020-2024 (%)
  • Exhibit 34: ROW - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 35: ROW - Year-over-year growth 2020-2024 (%)
  • Exhibit 36: Key leading countries
  • Exhibit 37: Market opportunity
  • Exhibit 38: Impact of drivers and challenges
  • Exhibit 39: Vendor landscape
  • Exhibit 40: Landscape disruption
  • Exhibit 41: Vendors covered
  • Exhibit 42: Vendor classification
  • Exhibit 43: Market positioning of vendors
  • Exhibit 44: Agilent Technologies Inc. - Vendor overview
  • Exhibit 45: Agilent Technologies Inc. - Business segments
  • Exhibit 46: Agilent Technologies Inc. - Organizational developments
  • Exhibit 47: Agilent Technologies Inc. - Geographic focus
  • Exhibit 48: Agilent Technologies Inc. - Segment focus
  • Exhibit 49: Agilent Technologies Inc. - Key offerings
  • Exhibit 50: ArcherDx Inc. - Vendor overview
  • Exhibit 51: ArcherDx Inc. - Product segments
  • Exhibit 52: ArcherDx Inc. - Organizational developments
  • Exhibit 53: ArcherDx Inc. - Key offerings
  • Exhibit 54: BGI Genomics Co. Ltd. - Vendor overview
  • Exhibit 55: BGI Genomics Co. Ltd. - Product segments
  • Exhibit 56: BGI Genomics Co. Ltd. - Organizational developments
  • Exhibit 57: BGI Genomics Co. Ltd. - Key offerings
  • Exhibit 58: Eurofins Scientific SE - Vendor overview
  • Exhibit 59: Eurofins Scientific SE - Business segments
  • Exhibit 60: Eurofins Scientific SE - Organizational developments
  • Exhibit 61: Eurofins Scientific SE - Segment focus
  • Exhibit 62: Eurofins Scientific SE - Key offerings
  • Exhibit 63: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 64: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 65: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 66: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 67: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 68: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 69: GENEWIZ Inc. - Vendor overview
  • Exhibit 70: GENEWIZ Inc. - Product segments
  • Exhibit 71: GENEWIZ Inc. - Organizational developments
  • Exhibit 72: GENEWIZ Inc. - Key offerings
  • Exhibit 73: Novogene Corp. - Vendor overview
  • Exhibit 74: Novogene Corp. - Product segments
  • Exhibit 75: Novogene Corp. - Organizational developments
  • Exhibit 76: Novogene Corp. - Key offerings
  • Exhibit 77: Personalis Inc. - Vendor overview
  • Exhibit 78: Personalis Inc. - Business segments
  • Exhibit 79: Personalis Inc. - Organizational developments
  • Exhibit 80: Personalis Inc. - Key offerings
  • Exhibit 81: QIAGEN NV - Vendor overview
  • Exhibit 82: QIAGEN NV - Business segments
  • Exhibit 83: QIAGEN NV - Organizational developments
  • Exhibit 84: QIAGEN NV - Geographic focus
  • Exhibit 85: QIAGEN NV - Key offerings
  • Exhibit 86: Thermo Fisher Scientific Inc. - Vendor overview
  • Exhibit 87: Thermo Fisher Scientific Inc. - Business segments
  • Exhibit 88: Thermo Fisher Scientific Inc. - Organizational developments
  • Exhibit 89: Thermo Fisher Scientific Inc. - Geographic focus
  • Exhibit 90: Thermo Fisher Scientific Inc. - Segment focus
  • Exhibit 91: Thermo Fisher Scientific Inc. - Key offerings
  • Exhibit 92: Validation techniques employed for market sizing
  • Exhibit 93: Definition of market positioning of vendors
Back to Top